CA hull investments boosts stake in Sequent Scientific to 61.4%

CA Hull Investments, along with its Persons Acting in Concert (PAC) CA Harbor Investments, announced a substantial acquisition of shares in Sequent Scientific Limited. This acquisition stems from a composite scheme of amalgamation involving Sequent Scientific and several other entities, including Viyash Life Sciences Private Limited. The scheme, sanctioned by the National Company Law Tribunal on November 18, 2025, resulted in Sequent Scientific allotting 13,61,60,231 equity shares to CA Hull Investments. Each share has a face value of INR 2/-.

This allotment to CA Hull Investments constitutes 31.20% of Sequent Scientific’s total paid-up share capital, changing its overall holding to 26,78,40,334 equity shares, representing 61.4% of the post-acquisition share capital. Previously, CA Hull Investments and PAC held 13,16,80,103 equity shares, or 52.33%. The share exchange ratio for Viyash shareholders was 56 fully paid-up equity shares of Sequent for every 100 fully paid-up equity shares of Viyash.

The acquisition is exempt from open offer obligations under Regulation 10(1)(d)(ii) of the SEBI Takeover Regulations, 2011, as it is part of a tribunal-approved scheme of arrangement. With this transaction, CA Hull Investments officially becomes part of Sequent Scientific's promoter group.